MENU
+Compare
APLS
Stock ticker: NASDAQ
AS OF
Oct 9, 04:59 PM (EDT)
Price
$25.73
Change
+$0.81 (+3.25%)
Capitalization
3.15B

APLS Apellis Pharmaceuticals Forecast, Technical & Fundamental Analysis

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade... Show more

APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for APLS with price predictions
Oct 08, 2025

APLS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for APLS moved above the 200-day moving average on September 22, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where APLS's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on October 03, 2025. You may want to consider a long position or call options on APLS as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for APLS just turned positive on October 06, 2025. Looking at past instances where APLS's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APLS advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

APLS moved below its 50-day moving average on October 08, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for APLS crossed bearishly below the 50-day moving average on September 23, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

APLS broke above its upper Bollinger Band on October 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for APLS entered a downward trend on October 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. APLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.121) is normal, around the industry mean (23.487). P/E Ratio (0.000) is within average values for comparable stocks, (54.584). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.216). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.131) is also within normal values, averaging (349.245).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

APLS is expected to report earnings to fall 581.82% to $1.59 per share on November 10

Apellis Pharmaceuticals APLS Stock Earnings Reports
Q3'25
Est.
$1.59
Q2'25
Beat
by $0.15
Q1'25
Missed
by $0.40
Q4'24
Beat
by $0.08
Q3'24
Missed
by $0.17
The last earnings report on July 31 showed earnings per share of -33 cents, beating the estimate of -47 cents. With 1.84M shares outstanding, the current market capitalization sits at 3.15B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Distributors
Address
100 Fifth Avenue
Phone
+1 617 977-5700
Employees
706
Web
https://www.apellis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGLYX19.390.31
+1.62%
JPMorgan Small Cap Growth R4
MCRFX15.230.05
+0.33%
BlackRock Mid-Cap Value Investor C
MSGAX12.20N/A
N/A
Meridian Small Cap Growth A
JVMTX29.86N/A
N/A
JHancock Disciplined Value Mid Cap R4
CSGTX4.10N/A
N/A
Transamerica Small Cap Growth C

APLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with DNLI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-1.15%
DNLI - APLS
46%
Loosely correlated
+5.03%
ARWR - APLS
44%
Loosely correlated
+1.09%
DYN - APLS
43%
Loosely correlated
+4.37%
VTYX - APLS
41%
Loosely correlated
-3.77%
APGE - APLS
41%
Loosely correlated
+18.90%
More